Rapid communicationsThe effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis☆
References (23)
- et al.
Sulindac causes regression of rectal polyps in familial adenomatous polyposis
Gastroenterology
(1991) - et al.
Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment
Gastroenterology
(1994) Kinetics of normal, preneoplastic, and neoplastic colonic epithelium
- et al.
Apoptosis and disease
Lancet
(1993) - et al.
p53-dependent apoptosis suppresses tumor growth and progression in vivo
Cell
(1994) - et al.
Non-steroidal antiinflammatory agents in chemoprevention of colorectal cancer—at what cost?
Dig Dis Sci
(1994) - et al.
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
N Engl J Med
(1993) - et al.
Sulindac for polyposis of the colon
Am J Surg
(1989) - et al.
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
Br J Surg
(1993) - et al.
Correlations between rectal mucosa cell proliferation and the clinical and pathological features of familial neoplasia of the large bowel
Cancer Res
(1991)
Features of apoptotic cells measured by flow cytometry
Cytometry
Cited by (238)
Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1)
2017, Biochimica et Biophysica Acta - BiomembranesCitation Excerpt :Especially compounds with existing pharmacological use were found as MRP1 inhibitors, such as the calcium antagonist verapamil, the immunosuppressant cyclosporine A [9], the organic anion transporter inhibitor probenecid [10], or several NSAIDs [11], e.g. indomethacin [12]. Some inhibitors were evaluated in clinical trials against cancer and cancer-related diseases, but with limited success due to severe side effects amongst other reasons [13,14,15,16,17]. Even compounds specifically designed to affect ABC transporters such as biricodar were clinically ineffective [18,19,20].
A review of the epidemiology of Barrett's oesophagus and oesophageal adenocarcinoma
2015, Best Practice and Research: Clinical GastroenterologyA novel role for villin in intestinal epithelial cell survival and homeostasis
2008, Journal of Biological ChemistrySulindac treatment in hereditary non-polyposis colorectal cancer
2007, European Journal of CancerCitation Excerpt :In cell culture studies, sulindac and sulindac sulphide indeed inhibited proliferation by inducing cell quiescence, with reduction of the expression of classical biomarkers of proliferation, such as Ki-67, independent of their ability to inhibit prostaglandin synthesis.3,13,15 However, these results were not consistently reproducible in in vivo studies, and conflicting data concerning effects of NSAIDs on the colorectal epithelial proliferation have been reported.11,21–25 A majority of the studies performed on biopsies from the rectosigmoid of patients with FAP failed to demonstrate an anti-proliferative effect of sulindac in normal colorectal mucosa.11,23,24
- ☆
Supported by the Clayton Fund, the McAshan Fund, and National Institutes of Health grants CA 53801-03 and 5P030 CA06973. Sulindac was kindly supplied by Merck, Sharpe and Dhome.